CME Group Inc (NASDAQ:CME) Shares Sold by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. decreased its position in shares of CME Group Inc (NASDAQ:CME) by 1.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 20,527 shares of the financial services provider’s stock after selling 401 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in CME Group were worth $4,120,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in CME. Evoke Wealth LLC purchased a new stake in CME Group in the 3rd quarter valued at about $27,000. CFM Wealth Partners LLC purchased a new stake in CME Group in the 4th quarter valued at about $30,000. Thor Advisors LLC purchased a new stake in CME Group in the 3rd quarter valued at about $34,000. Venturi Wealth Management LLC purchased a new stake in CME Group in the 3rd quarter valued at about $36,000. Finally, Sugarloaf Wealth Management LLC purchased a new stake in CME Group in the 4th quarter valued at about $36,000. 84.10% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ:CME opened at $213.13 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.03 and a quick ratio of 1.04. The firm has a market capitalization of $74.65 billion, a PE ratio of 30.63, a price-to-earnings-growth ratio of 4.68 and a beta of 0.14. The firm’s 50-day moving average is $208.21 and its two-hundred day moving average is $208.17. CME Group Inc has a 1 year low of $161.05 and a 1 year high of $224.91.

CME Group (NASDAQ:CME) last issued its quarterly earnings results on Wednesday, February 12th. The financial services provider reported $1.52 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.54 by ($0.02). The business had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.16 billion. CME Group had a return on equity of 9.22% and a net margin of 43.48%. The firm’s revenue for the quarter was down 7.9% on a year-over-year basis. During the same quarter last year, the company earned $1.77 earnings per share. Analysts expect that CME Group Inc will post 7.34 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be paid a dividend of $0.85 per share. The ex-dividend date is Monday, March 9th. This is a positive change from CME Group’s previous quarterly dividend of $0.75. This represents a $3.40 dividend on an annualized basis and a yield of 1.60%. CME Group’s dividend payout ratio is 44.12%.

Several analysts recently issued reports on CME shares. JPMorgan Chase & Co. reduced their price objective on shares of CME Group from $183.00 to $173.00 and set an “underweight” rating on the stock in a report on Friday, December 6th. Credit Suisse Group started coverage on shares of CME Group in a report on Monday, December 16th. They issued a “neutral” rating on the stock. Cfra boosted their price objective on shares of CME Group from $210.00 to $218.00 and gave the company a “hold” rating in a report on Thursday. Citigroup boosted their price objective on shares of CME Group from $220.00 to $240.00 and gave the company a “buy” rating in a report on Monday, October 21st. Finally, Sanford C. Bernstein lowered shares of CME Group from an “outperform” rating to a “market perform” rating in a report on Friday, January 10th. Four equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $209.17.

In other CME Group news, Director Martin J. Gepsman sold 1,000 shares of the business’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $201.16, for a total transaction of $201,160.00. Following the sale, the director now directly owns 34,905 shares in the company, valued at $7,021,489.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Terrence A. Duffy sold 39,309 shares of the business’s stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $202.38, for a total transaction of $7,955,355.42. Following the sale, the chief executive officer now owns 46,684 shares in the company, valued at $9,447,907.92. The disclosure for this sale can be found here. 1.20% of the stock is owned by corporate insiders.

About CME Group

CME Group Inc, through its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers a range of products across various asset classes, including futures and options based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities, and metals, as well as fixed income products.

Read More: What is the S&P/TSX Index?

Want to see what other hedge funds are holding CME? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CME Group Inc (NASDAQ:CME).

Institutional Ownership by Quarter for CME Group (NASDAQ:CME)

Receive News & Ratings for CME Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group and related companies with MarketBeat.com's FREE daily email newsletter.